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Introduction: An increasing number of cervical cancer survivors combined with lack 
of data on the efficacy of long-term surveillance, challenges existing follow-up mod-
els. However, before introducing new follow-up models, cervical cancer survivors’ 
own views on follow up are important. We aimed to explore preferences for follow 
up in long-term cervical cancer survivors and their associations with self-reported 
late-effects.
Material and methods: In 2013, we mailed 974 Norwegian long-term cervical cancer 
survivors treated during 2000-2007 a questionnaire with items covering preferences 
for follow up after treatment, clinical variables and validated questionnaires covering 
anxiety, neuroticism and depression.
Results: We included 471 cervical cancer survivors (response rate 57%) with a me-
dian follow up of 11 years. In all, 77% had FIGO stage I disease, and 35% were attend-
ing a follow-up program at the time of survey. Of the patients, 55% preferred more 
than 5 years of follow up. This was also preferred by 57% of cervical cancer survivors 
who were treated with conization only. In multivariable analyses, chemo-radiother-
apy or surgery with radiation and/or chemotherapy (heavy treatment) and younger 
age were significantly associated with a preference for more than 5 years’ follow up. 
Late effects were reported by more than 70% of the cervical cancer survivors who 
had undergone heavy treatment.
Conclusions: Our study reveals the need for targeted patient education about the 
benefits and limitations of follow up. To meet increasing costs of cancer care, indi-
vidualized follow-up procedures adjusted to risk of recurrence and late-effects in 
cervical cancer survivors are warranted.
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1  | INTRODUC TION
Over the past 20 years, the 5-year survival of cervical cancer pa-
tients has increased by 4%-14% worldwide according to reports 
from cancer registries in 64 countries.1 Five-year survival in Norway 
ranks among the highest in the world (81.4%).2 According to cur-
rent follow-up schedules in most western countries, cervical cancer 
patients are seen by a gynecologist for follow-up care 12-18 times 
within the first 5 years after primary treatment.3 Thereafter, some 
women continue a long-term, even lifelong, follow up in specialist 
care,3 as gynecologic oncologists tend to follow patients longer than 
the guidelines advise.3 However, long-term follow up is resource-
intensive, with unclear benefits for quality of life and survival for 
cervical cancer patients.4,5
Cervical cancer survivors range from women with very low risk 
of recurrence and low burden of late-effects to women with high 
burden of late-effects and/or high risk of recurrence.6,7 There is a 
shift towards more individualized and needs-assessed follow up of 
cervical cancer patients,8,9 and this is also debated in Norway. Prior 
to changing follow-up recommendations, it is important to identify 
surveillance preferences of cervical cancer survivors to better tailor 
patient information in future follow-up guidelines. Therefore, the 
aims of this study were to explore the prevalence and the determi-
nants of preferences for long-term (>5 years) follow up in a sample 
of Norwegian cervical cancer survivors. Further, we explored the 
associations between presence of late-effects and preferences for 
long-term follow up.
2  | MATERIAL AND METHODS
2.1 | Patients
Patients with cervical cancer diagnosed between 1 January 2000, 
and 31 December 2007 who were treated at hospitals located 
in the Health Regions of South Eastern Norway and Northern 
Norway, were identified in the Norwegian Cancer Registry. 
Inclusion criteria were 18-76 years of age at survey, ability to read 
Norwegian, no history of second cancer, considered tumor-free 
and not on any cancer treatment as of 31 December 2012. Eligible 
patients received a letter containing study information, a consent 
form and the survey questionnaire. Non-responders received one 
reminder.
2.2 | Organization of follow up
After treatment, Norwegian cervical cancer patients participate in 
a standard routine follow-up schedule according to the Norwegian 
national guidelines.10 The follow-up schedule recommends visits at 
a gynecological department three to four times annually the first 
2 years, twice a year over the next 3 years, and annually thereafter 
depending on the recommendations of the clinician. The follow-up 
visits are usually conducted by gynecology specialists or gyneco-
logic oncologists.
2.3 | Description of dependent variables
In the absence of a single, suitable, validated questionnaire on long-
term follow up after cervical cancer, relevant questions were devel-
oped by our research group (Table S1). For this purpose, studies of 
cancer survivors’ views on cancer follow up were reviewed and we 
included relevant issues identified in these studies.11,12 The question-
naire was thereafter piloted in eight cervical cancer survivors and five 
healthy women, and modified according to their feedback. In the pre-
sent study (n = 471), the Kuder–Richardson reliability coefficient was 
0.71 for the late-effects subscale. Late effects experienced by fewer 
than 5% of the cervical cancer survivors (ie coronary heart disease, 
osteoporosis and second cancer) were not included in the analyses.
2.4 | Demographic and clinical characteristics
A non-paired relationship described women not married or cohab-
iting. Low level of education was categorized as ≤12 school years 
completed vs high level of education (>12 years). Comorbidity was 
based on self-reported myocardial infarction, diabetes, chronic 
obstructive lung diseases, hypertension, rheumatic diseases (all 1 
point) and kidney disease (2 points) based on illness points according 
to Charlson et al.13 Self-rated health had five response alternatives 
and was dichotomized into good (excellent/very good/good) and 
poor (fair/poor).
Information on age, histology, International Federation of 
Gynecology and Obstetrics (FIGO) stage and previous treat-
ment was obtained from the medical records. The patients were 
treated according to Norwegian guidelines14 and divided into 
four treatment groups as described in a previous publication.15 
Group 1 was treated with conization. Group 2 was treated with 
major surgery in terms of radical hysterectomy with pelvic lymph 
node dissection with or without bilateral salpingo-oophorectomy. 
Group 3 was treated with external-beam pelvic radiation to the 
tumor and the regional lymph nodes, combined with brachyther-
apy, and concomitant low-dose cisplatin-containing chemotherapy 
(chemo-radiotherapy). A small subsample received neoadjuvant 
Key message
Of a cohort of long-term cervical cancer survivors, 55% 
preferred long-term (>5 years) follow up. Heavy treatment 
and younger age at survey were associated with the pref-
erence for long-term follow up. Cervical cancer survivors 
should be educated about the limited evidence of lifetime 
follow up.
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chemotherapy followed by standard major surgery (Group 4a). A 
few other patients had combinations of surgery and chemo-radio-
therapy (Group 4b). Due to small sample sizes, the Groups 4a and 
4b were merged into one group (Group 4) of surgery combined 
with either chemo-radiotherapy and/or neoadjuvant chemother-
apy. Patients who received treatment for recurrence were allo-
cated to the respective treatment group depending on treatment 
modality irrespective of primary treatment. As radiation therapy 
tends to cause more late-effects than surgery,6,7 we compared 
women treated with surgery only (Groups 1 + 2) vs those with 
more extensive treatment (Groups 3 + 4).
2.5 | Neuroticism
Neuroticism was self-rated on an abridged version of The Eysenck 
Personality Inventory16 with six items concerning personality char-
acteristics. The sum score ranged from zero to six, and was dichoto-
mized into the high (sum score 3-6) and low neuroticism (sum score 
0-2) group according to the procedure used in the third Health Study 
of North-Trøndelag County.17
2.6 | Anxiety
The Hospital Anxiety and Depression Scale comprised seven items 
each on the anxiety and depression subscales rated for the last 
week. The item scores ranged from 0 (not present) to 3 (highly pre-
sent), so the subscale scores ranged from 0 (low) to 21 (high). Only 
the anxiety subscale was adopted, and Cronbach’s alpha was 0.66.18 
Cases of potential clinical anxiety disorder were defined by a score 
of ≥8 on the anxiety subscale.18
2.7 | Depression
The Patient Health Questionnaire-9 contained nine items covering 
depression for the last 2 weeks, and each item was scored from 0 
(not at all) to 3 (nearly every day), providing a 0-27 severity score.19 
Cronbach’s alpha was 0.87 in the sample. Cases of potential clinical 
depression were defined by a score of ≥10.19
2.8 | Statistical analyses
Descriptive statistics was used to present demographic and clini-
cal characteristics of the sample. Continuous variables were de-
scribed with median and range, and categorical variables with 
numbers and percentages. The internal consistencies were ex-
amined with Cronbach’s coefficient alpha and Kuder-Richardson 
Formula 20 for dichotomous variables. Associations between 
independent variables and preference for more than 5 years of 
follow up as dependent variable (no preference for more than 
5 years follow up as reference) were examined with multivariable 
logistic regression analysis. The strength of associations was esti-
mated as odds ratios (ORs) with 95% confidence intervals (95% CI). 
Variables considered clinically relevant were tested for multicol-
linearity and then included in the multivariable analysis. We only 
included late-effects that differed significantly between cervical 
cancer survivors who preferred more vs less than 5 years of follow 
up in the model. The tests were two-sided and P < .05 were con-
sidered statistically significant. Analyses were performed using 
Statistical Package for the Social Sciences version 24 (IBM Corp., 
Armonk, NY, USA).
2.9 | Ethical approval
The study was approved by the Regional Committee for Medical and 
Health Research Ethics of South East Norway (#2013/634). The cer-
vical cancer survivors included in the study provided their written 
informed consent.
3  | RESULTS
In total, 822 (South Eastern Health Region) and 152 (Northern 
Health Region) cervical cancer survivors were invited to participate 
in the survey. Non-responders were sent one reminder, and 11 survi-
vors could not be located. A completed questionnaire were returned 
by 546 of 963 women (57% response rate). Thirty-five patients were 
excluded (22 due to another self-reported cancer, 40 patients due to 
recurrence of disease and 13 due to missing responses to the follow-
up items). Accordingly, 471 cervical cancer survivors were included 
in the study analysis. Demographic and clinical characteristics of the 
participants are summarized in Table 1.
3.1 | Preference for long-term follow up
Of the cervical cancer survivors, 55% (n = 259) preferred long-term 
follow up (Table 1); 52% of them were attending regular follow-up 
visits at the time of the survey, a median time of 11 years (range 
6-15) since diagnosis. In contrast, 212 survivors (45%) reported no 
need for long-term follow up, although 11% were still attending 
regular follow up. Significantly more women in treatment Groups 
3 + 4 (hereafter “heavily treated”) preferred long-term follow up 
compared with the surgery group (P = .007). However, 57% in treat-
ment Group 1 (conization) preferred long-term follow up and 29% 
attended regular follow-up visits at the time of the survey.
In the multivariable logistic regression analysis, heavy treatment 
and younger age were significantly associated with the preference 
for long-term follow up (Table 2).
Regarding the preferred level of care providing follow up, 69% 
of the cancer survivors preferred a gynecologist (59% gynecologists 
at hospitals, 10% gynecologists in private practice) and 2% a general 
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practitioner, and 29% stated that the quality of follow up was more 
important than the profession of the provider.
3.2 | Self-reported late-effects
Late-effects were most frequently reported in treatment Groups 
3 + 4 (Figure 1). Furthermore, 83% of the women in treatment Group 
4 reported multiple late-effects compared with 31% in treatment 
group 1 (Figure 2). Cervical cancer survivors in treatment Groups 
3 + 4 reported significantly more intestinal problems (P < .001), uri-
nary problems (P < .001), sexual problems (P < .001), and fatigue 
(P < .001) (Figure 1). Lymph edema was associated significantly more 
(P < .001) with surgery (treatment Groups 2 + 4), and 44% women 
reported this problem in treatment Group 4, compared with 29% 
in treatment Group 2. In the total sample, anxiety and depression 
scores indicated that 54% of women had an anxiety disorder and 
18% a depression disorder (Table 1). There were no significant dif-
ferences in self-reported late-effects between women who pre-
ferred long-term follow-up care and those who did not (Table 3).
4  | DISCUSSION
To our knowledge, this is the first study to investigate preferences 
for long-term follow up among recurrence-free long-term cervical 
TA B L E  1   Characteristics of long-term cervical cancer survivors and their preference for long-term follow up
 
Preference for >5 y 
follow up (n = 259)
No preference for >5 y 
follow up (n = 212) P value
Total sample, 
n = 471
Age at diagnosis (y), median (range) 40 (23-66) 42 (24-68) .49 41 (24-68)
Age at survey (y), median (range) 51 (32-75) 54 (33-76) .46 53 (32-76)
Histology, n (%)
Squamous cell carcinoma 185 (71) 162 (77) .59 347 (74)
Adenocarcinoma + other non-squamous cell 
carcinoma
69 (27) 45 (21)  114 (24)
Unknown 5 (2) 5 (2)  10 (2)
FIGO stages, n (%)
Stage 1A 80 (31) 83 (39) .37 163 (35)
Stage 1B 113 (43) 86 (41)  199 (42)
Stage 2 49 (19) 35 (16)  84 (18)
Stage 3 10 (4) 6 (3)  16 (3)
Stage 4 4 (2) 0  4 (1)
Unstaged 3 (1) 2 (1)  5 (1)
Treatment, n (%)
Conization 48 (19) 36 (17) .01 84 (18)
Major surgerya  107 (41) 116 (55)  223 (47)
Chemo-radiotherapy 60 (23) 41 (19)  101 (21)
Major surgery + radiation and/or chemotherapy 44 (17) 19 (9)  63 (14)
In paired relationship, n (%) 183 (71) 140 (66) .28 323 (69)
Level of education, n (%)
Low (<12 y) 134 (52) 128 (60) 0.07 262 (56)
High (≥12 y) 125 (48) 84 (40)  205 (44)
Comorbidity index, n (%)
0 point 188 (72) 142 (67) .054 330 (70)
1 point 59 (23) 48 (23)  107 (23)
≥2 points 12 (5) 22 (10)  34 (7)
Daily smoking, n (%) 53 (21) 39 (18) .57 92 (20)
Poor self-rated health 63 (24) 49 (23) .71 112 (24)
Anxiety sum ≥8, n (%) 140 (54) 114 (54) .95 254 (54)
Neuroticism score ≥3, n (%) 104 (40) 78 (37) .54 182 (39)
Depression score ≥10, n (%) 46 (18) 39 (18) .91 85 (18)
aMajor surgery: radical hysterectomy with pelvic lymph node dissection with or without bilateral salpingo-ophorectomy. 
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cancer survivors. At a median of 11 years after diagnosis, a major-
ity (55%) of the survivors preferred more than 5 years of follow up. 
Heavy treatment and younger age were associated with a preference 
for long-term follow up in the multivariable analyses. Women with 
heavier treatment experienced more late-effects than those treated 
with surgery only. However, presence of late-effects were not signifi-
cantly associated with a need for long-term follow up in the analyses.
As shown in a review study on patient preferences for follow up 
after cancer, patients appear to lose confidence in their bodies and 
fear cancer recurrence even after treatment for low-risk cancer.20 
Further, after treatment, the patients find regular visits important to 
reassure them that they have no recurrence, as they expect recur-
rences to be detected at the follow-up visits.20,21 This may explain 
the need for more than 5 years follow up among the majority of the 
survivors. In the multivariable modeling, we found an association 
between heavy treatment and a preference for long-term follow 
up. A possible explanation is that patients with higher-risk tumors 
are likely to receive heavy treatment and consequently be recom-
mended long-term follow up, which may influence their preferences 
5 years after treatment. As expected, women with heavy treatment 
reported more late-effects compared with those treated with sur-
gery only. On the other hand, late-effects were not associated with 
a preference for long-term follow up, suggesting that this is not the 
reason why heavy treatment is associated with a preference for 
long-term follow up. However, there was a tendency towards more 
hormonal changes (P = .07) and intestinal problems (P = .08) among 
those who preferred long-term follow up. As shown in Figure 1, in-
testinal and urinary late-effects, as well as sexual late-effects and 
lymph edema were the most frequently reported among the partici-
pants, which is in line with the literature.22
The prevalence of self-reported anxiety (54%) and depression 
(18%) among the cervical cancer survivors in our study is similar to 
findings in other studies of long-term cervical cancer survivors.23,24 
However, we did not find any association between preferences for 
longer follow up and depression, anxiety and personality traits such 
as neuroticism.
The participants preferred follow-up care to be performed by 
hospital specialists, which has been reported before.21 This may be 
explained by the fact that most follow-up visits are performed in 
hospitals and that patients tend to favor the existing service. In a 
study on the attitudes of gynecological cancer survivors towards 
follow up, those who had not yet started follow up were more will-
ing to be followed up by a general practitioner, as opposed to those 
who had attended hospital follow up for longer time, who preferred 
hospital specialists.21
The purposes of cancer follow up are to detect recurrences that 
are amenable to treatment providing cure or long-term survival, to 
detect and treat early- and late-effects, and to offer psychological 
support after treatment.25 Whether routine surveillance for early 
detection of recurrence with distant metastases improves cervical 
cancer survival is not documented.26 However, patients with local re-
currences may be candidates for curative radiation27 or, in rare cases, 
for pelvic exenteration with curative intention.28 Approximately 80% 
of recurrences of cervical cancer occur within 2-3 years after treat-
ment,26,29 and the value of continued follow up is debated.5 There is 
evidence that routine visits can induce stress during follow up,30 and 
many gynecological cancer survivors report anxiety before and relief 
after the visits, based on fear of a recurrence that will most likely 
TA B L E  2   A multivariable logistic regression model of 
associations between clinical characteristics and preference of 
long-term follow up in cervical cancer survivors
Variables OR 95% CI P value
    
Age at diagnosis 1.02 1.00-1.04 .035
Education >12 y 1.45 0.97-2.18 .072
Treatment Group 3 + 4 2.06 1.32-3.21 .001
Poor self-rated health 0.92 0.60-1.41 .71
Comorbidity   .06
0 point (reference) 1.00 — —
1 point 1.08 0.65-1.67 .74
≥2 points 2.43 1.16-5.06 .02
HADS-anxietya  0.98 0.68-1.41 .92
Neuroticism 0.89 0.61-1.29 .54
PHQ depressiona  1.03 0.64-1.65 .91
aHADS-Anxiety and PHQ-9 Depression correlated moderately with 
Spearman’s coefficient rho 0.30. 
F I G U R E  1   Self-reported late-effects 
in four treatment groups reported as 
percentage within each group [Color 
figure can be viewed at wileyonlinelibrary.
com]
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never occur.30 In the present study, 57% of the cervical cancer survi-
vors treated with conization preferred long-term follow up. This was 
unexpected, as this group of patients both has an excellent prognosis 
and reports low levels of late-effects. One reason may be lack of in-
formation on the limited evidence of long-term follow up effects on 
overall survival. Another reason may be the clinician’s difficulties in 
terminating follow-up care. Our findings imply that targeted informa-
tion at the end of treatment on the benefits and limitations of routine 
follow up is important, letting the patients know what to expect from 
the follow-up care. Through shared decision making, it important to 
plan how long the routine visits will continue. Given that most recur-
rences occur within 3 years after treatment26,29 and that follow-up 
visits are time-consuming and expensive for both the patient and 
the clinician, the value of continued follow up for more than 3 years 
in a hospital setting is debatable, especially in low-risk cervical can-
cer survivors. New models for follow-up care are emerging and one 
of the models proposed is a risk-stratified follow-up model where 
cancer survivors are stratified into low, moderate or high-risk based 
on risk of recurrence and expected late-effects.25
A strength of our study is the use of validated self-rating in-
struments with established psychometric properties, apart from 
the questionnaire on preferences for follow up. However, the latter 
was piloted before being utilized in the study. Another strength is 
the population-based recruitment from two of Norway’s five health 
regions with the highest incidence of cervical cancer in Norway.2 
A limitation of our study is the lack of assessment of details of pre-
ferred follow up such as frequency of routine visits, and the number 
of years they had attended routine follow up since end of treat-
ment. Further, we did not assess physician factors related to long-
term follow up. Though our response rate of 57% at a median of 
11 years post diagnosis is acceptable, the external validity of our 
findings may have been compromised by respondent selection bias, 
and it is unclear how this would affect preference estimates for 
follow-up care strategies. In addition, lack of data allowing for an 
attrition analysis characterizing the non-respondents is a limitation. 
Finally, since we only have cross-sectional data, we can only pres-
ent significant associations between variables, rather than causal 
findings.
5  | CONCLUSION
Our study highlights that cervical cancer survivors need to be edu-
cated about the effectiveness of follow-up examinations and the 
limited evidence for lifetime follow up. Long-term follow up of low-
risk non-symptomatic cervical cancer survivors may support an un-
necessary fear of cancer recurrence. While efforts are ongoing to 
improve cervical cancer survivors’ long-term prognosis, it should be 
F I G U R E  2   Number of self-reported 
late-effects in four treatment groups 
[Color figure can be viewed at 
wileyonlinelibrary.com]





up, (N = 259) 
n (%)
No preference of 
long-term follow 




Hormonal changes 64 (25) 38 (18) .07
Reduced fertility 45 (17) 25 (12) .09
Chronic fatigue 59 (23) 39 (18) .24
Intestinal problems 77 (30) 48 (23) .08
Bladder problems 73 (28) 55 (26) .59
Sexual problems 70 (27) 44 (21) .11
Lymphedema 67 (26) 54 (26) .92
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possible to create more individualized follow-up programs adjusted 
to risk of recurrence and late-effects in cervical cancer survivors.
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